84. サルコイドーシス Sarcoidosis Clinical trials / Disease details


臨床試験数 : 149 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05696795
(ClinicalTrials.gov)
May 1, 202313/1/2023Janus Kinase Inhibition in SarcoidosisJAK1 Inhibition in Sarcoidosis: an Opportunity for Pathogenesis Directed TherapySarcoidosisDrug: Abrocitinib 200 mgYale UniversityPfizerNot yet recruiting18 YearsN/AAll10Phase 2United States
2NCT05689879
(ClinicalTrials.gov)
February 7, 20232/5/2022Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in SarcoidosisEvaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis : a Prospective, Randomized, Controlled TrialSarcoidosisDrug: STOP armAssistance Publique - Hôpitaux de ParisNULLNot yet recruiting18 YearsN/AAll90Phase 3NULL
3NCT05499637
(ClinicalTrials.gov)
November 15, 202222/6/2022[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial InflammationPilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor PET/CT in the Diagnosis of Three Clinical Entities of Acute Myocardial InflammationAcute Cellular Graft Rejection;Cardiac Sarcoidosis;Myocarditis Due to DrugDrug: [68Ga]Ga-PentixaFor PET/CTJohn O. PriorNULLRecruiting18 YearsN/AAll69Phase 2Switzerland
4NCT05415137
(ClinicalTrials.gov)
September 15, 20228/6/2022Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisPulmonary SarcoidosisDrug: Efzofitimod 3 mg/kg;Drug: Efzofitimod 5 mg/kg;Drug: PlaceboaTyr Pharma, Inc.Kyorin Pharmaceutical Co.,LtdRecruiting18 Years75 YearsAll264Phase 3United States;Japan;Netherlands;Puerto Rico;Spain
5EUCTR2021-004794-31-NL
(EUCTR)
01/07/202210/05/2022A study to Assess the Efficacy and Safety of Namilumab in subjects with lung inflammatory diseaseA Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis - Resolve-Lung chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Namilumab
Product Code: KIN-1902
INN or Proposed INN: NAMILUMAB
Kinevant Sciences GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 2France;United States;Belgium;Turkey;Germany;Netherlands;United Kingdom
6NCT05351554
(ClinicalTrials.gov)
June 30, 20224/4/2022A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac SarcoidosisA Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac SarcoidosisSarcoidosis, CardiacDrug: Namilumab;Drug: Placebo;Drug: Open label NamilumabKinevant Sciences GmbHNULLTerminated18 YearsN/AAll1Phase 2United States
7NCT05314517
(ClinicalTrials.gov)
April 30, 202230/3/2022A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary SarcoidosisA Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary SarcoidosisSarcoidosis, PulmonaryDrug: Namilumab;Drug: PlaceboKinevant Sciences GmbHNULLRecruiting18 YearsN/AAll100Phase 2United States;Belgium;France;Netherlands
8NCT05247554
(ClinicalTrials.gov)
March 1, 20229/2/2022Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary SarcoidosisRandomized Controlled Trial Testing the Effect of Hydroxychloroquine Combined With Low-dose Corticosteroid Therapy in Pulmonary SarcoidosisPulmonary SarcoidosisDrug: Hydroxychloroquine + low-dose prednisone;Drug: PrednisoneAssistance Publique - Hôpitaux de ParisNULLNot yet recruiting18 Years80 YearsAll200Phase 3NULL
9NCT04924270
(ClinicalTrials.gov)
January 20227/6/2021Safety and Efficacy of Faecal Microbiota Transplantation in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory DiseasesSafety and Clinical Efficacy Associated With Faecal Microbiota Transplantation Performed in Treatment-naïve Patients With Newly Diagnosed Rheumatoid Arthritis, Reactive Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Gouty Arthritis, Psoriasis, Hidradenitis Suppurativa, Pulmonary Sarcoidosis, Crohn's Disease, and Ulcerative Colitis: a 52-week, Double-blind, Randomised, Placebo-controlled, Exploratory TrialRheumatoid Arthritis;Reactive Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis;Gouty Arthritis;Psoriasis;Hidradenitis Suppurativa;Pulmonary Sarcoidosis;Crohn Disease;Ulcerative ColitisBiological: Faecal microbiota transplantation;Other: PlaceboTorkell EllingsenRegion of Southern Denmark;University of Southern DenmarkNot yet recruiting18 Years70 YearsAll200Phase 2NULL
10JPRN-jRCTs011210048
05/11/202105/11/2021Cardiac Sarcoidosis Multi-Center Randomized Controlled TrialCardiac Sarcoidosis Multi-Center Randomized Controlled Trial - CHASM CS- RCT Cardiac Sarcoidosis
Cardiac Sarcoidosis
Subjects meeting the study inclusion/exclusion criteria will be randomized equally to receive either:

1. Prednisone 0.5 mg kg/day for 6-months (MAX dose 30 mg per day) or

2. Methotrexate 15-20 mg po, sc, or IM once a week for 6-months + Folic Acid 2 mg OD for 6 months + Prednisone 20 mg day for 1 month, then 10 mg OD for 1 month, then 5 mg OD for one month then STOP
Toshiyuki NagaiNULLPending>= 18age oldNot applicableBoth194Phase 3Canada;United States;United Kingdom;Japan
11EUCTR2017-004219-37-DE
(EUCTR)
16/03/202129/07/2020Influence of Inhaled Aviptadil on Cough and Quality of life in SarcoidosisA randomized, prospective, multicenter, controlled and double-blinded Phase II Clinical Trial to evaluate the influence of inhaled Aviptadil on Cough and Quality of Life in Sarcoidosis patients - Avisarco II Pulmonary sarcoidosis associated with cough
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: Aviptadil
INN or Proposed INN: Aviptadil
Other descriptive name: AVIPTADIL
Universitätsklinikum Freiburg, Leitender Ärztlicher DirektorUniversitätsklinikum Freiburg, Kaufmännische DirektorinAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Phase 2Germany
12NCT03942211
(ClinicalTrials.gov)
February 26, 20217/5/2019A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral SelexipagA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Sarcoidosis-Associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.Sarcoidosis-associated Pulmonary HypertensionDrug: Selexipag;Drug: PlaceboActelionNULLActive, not recruiting18 Years75 YearsAll10Phase 2United States;Belgium;Brazil;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;Czechia
13NCT04758650
(ClinicalTrials.gov)
January 26, 202112/2/2021Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and Cardiac sarcoïdosis.Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions,Cardiovascular Atherosclerosis,Syndrome With Abnormal Immune Activation and Cardiac sarcoïdosisSquamous Cell Carcinoma of Head and Neck;Cancer;Carotid Stenosis;Atherosclerosis of Artery;Hodgkin Lymphoma, Adult;Non Hodgkin Lymphoma;HLH;Cardiac SarcoidosisDrug: 68GaNOTA-Anti-MMR-VHH2Universitair Ziekenhuis BrusselNULLRecruiting18 YearsN/AAll140Phase 2Belgium
14EUCTR2018-000381-11-GB
(EUCTR)
09/11/202016/06/2020Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis Chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: CMK389
INN or Proposed INN: CMK389
Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
66Phase 2United States;Czech Republic;Poland;Denmark;Germany;United Kingdom
15NCT04017936
(ClinicalTrials.gov)
October 23, 20209/7/2019Interleukin-1 Blockade for Treatment of Cardiac SarcoidosisInterleukin-1 Blockade for Treatment of Cardiac SarcoidosisCardiac SarcoidosisDrug: AnakinraVirginia Commonwealth UniversityAmerican Heart Association;National Center for Advancing Translational Sciences (NCATS)Recruiting21 YearsN/AAll28Phase 2United States
16EUCTR2018-000381-11-PL
(EUCTR)
06/10/202023/07/2020Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis Chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: CMK389
INN or Proposed INN: CMK389
Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
66Phase 2United States;Czechia;Poland;Denmark;Germany;United Kingdom
17ChiCTR2000036043
2020-10-012020-08-21A prospective, single-centre, diagnostic accuracy study of XpertMTB/RIF Ultra to differentiate atypical tuberculosis from sarcoidosisA prospective, single-centre, diagnostic accuracy study of XpertMTB/RIF Ultra to differentiate atypical tuberculosis from sarcoidosis sarcoidosis, tuberculosisGold Standard:Biopsy pathological specimen, and sputum AFB smear;Index test:XpertMTB/RIF Ultra;Shanghai Pulmonary Hospital Tongji University, School of MedicineNULLPending18BothTarget condition:72;Difficult condition:72China
18NCT02523092
(ClinicalTrials.gov)
October 202010/8/2015Use of CXCL9 as a Biomarker of Acthar EfficacyUse of CXCL9 as a Biomarker of Acthar EfficacySarcoidosisDrug: Acthar gelUniversity of California, San FranciscoMallinckrodtNot yet recruiting18 Years65 YearsAll14Phase 4United States
19NCT04064242
(ClinicalTrials.gov)
September 23, 202020/8/2019Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisPulmonary SarcoidosisDrug: CMK389;Drug: PlaceboNovartis PharmaceuticalsNULLRecruiting18 Years75 YearsAll66Phase 2United States;Czechia;Denmark;Germany;Poland;United Kingdom
20EUCTR2018-000381-11-DK
(EUCTR)
24/08/202030/06/2020Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis Chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: CMK389
INN or Proposed INN: CMK389
Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
66Phase 2United States;Czechia;Poland;Denmark;Germany;United Kingdom
21NCT05524077
(ClinicalTrials.gov)
July 8, 202024/8/2022Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular TachycardiaCatheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT): A Randomised TrialHeart Disease Structural Disorder;Ventricular Tachycardia;Cardiomyopathy, Dilated;Sarcoidosis;Cardiomyopathy, Hypertrophic;Cardiomyopathy Ischemic;Cardiomyopathy, Familial;Arrhythmogenic Right Ventricular Cardiomyopathy 1;Arrhythmogenic Left Ventricular CardiomyopathyProcedure: Ablation;Drug: Anti-arrhythmic Drugs (AADs)Western Sydney Local Health DistrictNULLRecruiting18 YearsN/AAll162N/AAustralia
22EUCTR2018-000381-11-DE
(EUCTR)
16/06/202031/01/2020Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoidosis Chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Code: CMK389
INN or Proposed INN: CMK389
Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
66Phase 2United States;Czechia;Poland;Denmark;Germany;United Kingdom
23NCT04314193
(ClinicalTrials.gov)
June 1, 202024/2/2020Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary SarcoidosisThe PREDMETH Trial: Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis - A Randomized Controlled TrialSarcoidosis, PulmonaryDrug: Methotrexate;Drug: PrednisoloneErasmus Medical CenterSt. Antonius Hospital;LongfondsRecruiting18 YearsN/AAll138Phase 4Netherlands
24EUCTR2018-004887-74-DE
(EUCTR)
20/05/202017/06/2019A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension.A Multicenter, Randomized, Double-blind, Placebo-controlled study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. sarcoidosis-associated pulmonary hypertension (SAPH)
MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Uptravi
Product Name: Selexipag
Product Code: ACT-293987 / JNJ-67896049
INN or Proposed INN: SELEXIPAG
Other descriptive name: SELEXIPAG
Actelion Pharmaceuticals LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
74Phase 2United States;Czechia;Spain;Italy;United Kingdom;France;Hungary;Canada;Brazil;Belgium;Poland;Germany;Netherlands
25NCT04320121
(ClinicalTrials.gov)
March 11, 202017/3/2020Effect of Nelutri™ on Musculoskeletal Biomarkers in Relative Sarcopenia AdultsEffect of Nelutri™ on Musculoskeletal Biomarkers in Relative Sarcopenia Adults: a Randomized, Double-blinded, Placebo-controlled TrialMuscular SarcoidosisDietary Supplement: Nelutri™;Dietary Supplement: Placebo groupPusan National University Yangsan HospitalNULLCompleted19 MonthsN/AAll80N/AKorea, Republic of
26EUCTR2019-004148-31-NL
(EUCTR)
26/02/202015/11/2019The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trialThe PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial - PREDMETH trial pulmonary sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Methotrexate
Product Name: methotrexate
INN or Proposed INN: methotrexate
Other descriptive name: METHOTREXATE
Trade Name: Prednison
Product Name: Prednison
INN or Proposed INN: prednisone
Other descriptive name: PREDNISONE
Erasmus Medisch Centrum Dept. of PulmonologyNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
132Phase 4Netherlands
27NCT03814317
(ClinicalTrials.gov)
January 30, 20204/1/2019Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary HypertensionAn Open-Label Study of Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension and Interstitial Lung Disease (SAPPHIRE)Sarcoidosis;Precapillary Pulmonary Hypertension;Interstitial Lung DiseaseDrug: Inhaled TreprostinilUniversity of FloridaUnited TherapeuticsRecruiting18 Years99 YearsAll10Phase 2United States
28NCT04206163
(ClinicalTrials.gov)
January 20, 202013/12/2019Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac SarcoidosisSomatostatin Receptor Imaging in Inflammatory Heart DiseaseAcute Myocarditis;Cardiac SarcoidosisDiagnostic Test: 68Ga-DOTA-TOC PET/CT;Biological: Blood sampleVastra Gotaland RegionNULLRecruiting18 Years85 YearsAll80N/ASweden
29EUCTR2018-004244-33-DE
(EUCTR)
21/10/201915/07/2019A safety study with multiple doses of intravenous (in the vein) ATYR1923 in patients with pulmonary sarcoidosisA Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis Pulmonary Sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: ATYR1923
Product Code: ATYR1923
INN or Proposed INN: Not yet available
Other descriptive name: iMod.Fc, H-Fcv3-N4
aTyr Pharma, Inc.NULLNot Recruiting Female: yes
Male: yes
36 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Germany
30NCT04109911
(ClinicalTrials.gov)
September 25, 201927/9/2019Effect of Fermented Oyster Extract on Musculoskeletal Biomarkers in Relative Sarcopenia AdultsEffect of Fermented Oyster Extract on Musculoskeletal Biomarkers in Relative Sarcopenia Adults: a Randomized, Double-blinded, Placebo-controlled TrialMuscular SarcoidosisDietary Supplement: Fermented oyster extract;Dietary Supplement: PlaceboPusan National University Yangsan HospitalNULLCompleted50 YearsN/AAll54N/AKorea, Republic of
31EUCTR2018-004887-74-IT
(EUCTR)
13/09/201917/06/2021A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension.A multicenter, randomized, double-blind, placebo-controlled study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the efficacy and safety of oral selexipag. - AC-065D301 sarcoidosis-associated pulmonary hypertension (SAPH)
MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Uptravi
Product Name: Selexipag
Product Code: [ACT-293987 / JNJ-67896049]
INN or Proposed INN: selexipag
Other descriptive name: selexipag
ACTELION PHARMACEUTICALS LTDNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
74Phase 2;Phase 3United States;Czechia;Spain;Italy;United Kingdom;France;Hungary;Canada;Brazil;Belgium;Poland;Germany;Netherlands
32NCT04020380
(ClinicalTrials.gov)
September 6, 201911/7/2019Azithromycin a Treatment for Pulmonary SarcoidosisA Single Arm, Open-label Exploratory Clinical Trial of Azithromycin in Pulmonary SarcoidosisSarcoidosis, PulmonaryDrug: Azithromycin 250Mg CapsuleHull University Teaching Hospitals NHS TrustNULLCompleted18 Years80 YearsAll21Phase 2United Kingdom
33NCT04008069
(ClinicalTrials.gov)
September 3, 201925/6/2019Sarilumab in Patients With Glucocorticoid-Dependent SarcoidosisA Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent SarcoidosisSarcoidosisDrug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1;Drug: PlacebosStanford UniversityNULLCompleted18 Years80 YearsAll15Phase 2United States
34EUCTR2018-004887-74-HU
(EUCTR)
29/08/201925/06/2019A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension.A multicenter, randomized, double-blind, group-sequential, placebo-controlled 52-week period followed by a 104-week, single-arm, open-label period study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the efficacy and safety of oral selexipag. sarcoidosis-associated pulmonary hypertension (SAPH)
MedDRA version: 20.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Uptravi
Product Name: Selexipag
Product Code: ACT-293987 / JNJ-67896049
INN or Proposed INN: SELEXIPAG
Other descriptive name: SELEXIPAG
Actelion Pharmaceuticals LtdNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
150 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noPortugal;United States;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Denmark;Netherlands;Germany;China;Sweden
35EUCTR2018-004887-74-ES
(EUCTR)
19/08/201904/07/2019A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension.A multicenter, randomized, double-blind, group-sequential, placebo-controlled 52-week period followed by a 104-week, single-arm, open-label period study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the efficacy and safety of oral selexipag. sarcoidosis-associated pulmonary hypertension (SAPH)
MedDRA version: 20.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Uptravi
Product Name: Selexipag
Product Code: ACT-293987 / JNJ-67896049
INN or Proposed INN: SELEXIPAG
Other descriptive name: SELEXIPAG
Actelion Pharmaceuticals LtdNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
150 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noPortugal;United States;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Denmark;Netherlands;Germany;China;Sweden
36EUCTR2018-004887-74-GB
(EUCTR)
14/08/201903/06/2019A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension.A Multicenter, Randomized, Double-blind, Placebo-controlled Study inParticipants with Sarcoidosis-associated Pulmonary Hypertension (SAPH)to Assess the Efficacy and Safety of Oral Selexipag. sarcoidosis-associated pulmonary hypertension (SAPH)
MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Uptravi
Product Name: Selexipag
Product Code: ACT-293987 / JNJ-67896049
INN or Proposed INN: SELEXIPAG
Other descriptive name: SELEXIPAG
Actelion Pharmaceuticals LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
74Phase 2United States;Czechia;Spain;United Kingdom;Italy;France;Hungary;Canada;Belgium;Brazil;Poland;Germany;Netherlands
37EUCTR2018-004887-74-PL
(EUCTR)
13/08/201926/06/2019A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension.A multicenter, randomized, double-blind, group-sequential, placebo-controlled 52-week period followed by a 104-week, single-arm, open-label period study in participants with sarcoidosis-associated pulmonary hypertension (SAPH) to assess the efficacy and safety of oral selexipag. sarcoidosis-associated pulmonary hypertension (SAPH)
MedDRA version: 20.0;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Uptravi
Product Name: Selexipag
Product Code: ACT-293987 / JNJ-67896049
INN or Proposed INN: SELEXIPAG
Other descriptive name: SELEXIPAG
Actelion Pharmaceuticals LtdNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
150 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noPortugal;United States;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Romania;Denmark;Netherlands;Germany;China;Sweden
38EUCTR2018-004887-74-NL
(EUCTR)
29/07/201905/06/2019A study of the effectiveness and safety of selexipag in patients with sarcoidosis-associated pulmonary hypertension.A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. sarcoidosis-associated pulmonary hypertension (SAPH)
MedDRA version: 21.1;Level: PT;Classification code 10037400;Term: Pulmonary hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Uptravi
Product Name: Selexipag
Product Code: ACT-293987 / JNJ-67896049
INN or Proposed INN: SELEXIPAG
Other descriptive name: SELEXIPAG
Actelion Pharmaceuticals LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
74Phase 2France;United States;Hungary;Canada;Poland;Spain;Belgium;Brazil;Germany;Netherlands;United Kingdom;Italy
39EUCTR2019-000580-24-GB
(EUCTR)
17/05/201925/03/2019A clinical trial of the antibiotic azithromycin for patients with sarcoidosisA single arm, open-label clinical trial of azithromycin in pulmonary sarcoidosis - Azithromycin for sarcoidosis Sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Azithromycin
Product Name: Azithromycin
INN or Proposed INN: azithromycin monohydrate
Hull & East Yorkshire Hospitals NHS trustNULLNot RecruitingFemale: yes
Male: yes
30Phase 2United Kingdom
40NCT03793439
(ClinicalTrials.gov)
May 15, 20192/1/2019Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent SarcoidosisTofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent SarcoidosisSarcoidosis, Pulmonary;Sarcoidosis Lung;SarcoidosisDrug: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial;Diagnostic Test: Spirometry;Genetic: RNA Sequencing;Diagnostic Test: Laboratory testing;Drug: Corticosteroid;Drug: Tofacitinib 5mg [Xeljanz] 1 year open-label extensionOregon Health and Science UniversityPfizerRecruiting18 Years89 YearsAll5Phase 1United States
41NCT03910543
(ClinicalTrials.gov)
April 11, 20194/4/2019Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma AnnulareOpen-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma AnnulareCutaneous Sarcoidosis;Granuloma AnnulareDrug: Tofacitinib 5 mg twice dailyYale UniversityPfizerCompleted18 YearsN/AAll15Phase 1United States
42NCT03704610
(ClinicalTrials.gov)
March 28, 201910/10/2018Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES)Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES STUDY)Extrathoracic SarcoidosisDrug: Infliximab;Drug: PlaceboAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/AAll31Phase 3France
43EUCTR2017-004930-27-AT
(EUCTR)
05/02/201920/12/2018Sirolimus as treatment for patients with sarcoidosis.Systems medicine analysis of sarcoidosis by targeting mTOR in apilot study of sirolimus as treatment in patients with sarcoidosis Sarcoidosis with cutaneous affections;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Rapamune
INN or Proposed INN: SIROLIMUS
Other descriptive name: Rapamune
Product Name: Sirolimus Ointment
INN or Proposed INN: SIROLIMUS
Medical University of ViennaNULLNot RecruitingFemale: yes
Male: yes
20Phase 2Austria
44NCT02920710
(ClinicalTrials.gov)
February 1, 201929/9/2016ACTHAR Therapy for Central Nervous System SarcoidosisACTHAR Therapy for Central Nervous System SarcoidosisSarcoidosisDrug: Repository Corticotropin InjectionThe Cleveland ClinicMallinckrodtWithdrawnN/AN/AAll0Phase 4United States
45NCT03824392
(ClinicalTrials.gov)
January 29, 201928/1/2019Study of Intravenous ATYR1923 for Pulmonary SarcoidosisA Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary SarcoidosisPulmonary SarcoidosisBiological: ATYR1923 1.0 mg/kg or placebo;Biological: ATYR1923 3.0 mg/kg or placebo;Biological: ATYR1923 5.0 mg/kg or placeboaTyr Pharma, Inc.Foundation for Sarcoidosis ResearchCompleted18 Years75 YearsAll37Phase 1/Phase 2United States
46NCT03593759
(ClinicalTrials.gov)
January 15, 201927/6/2018Cardiac Sarcoidosis Randomized TrialCardiac Sarcoidosis Multi-Center Randomized Controlled TrialCardiac Sarcoidosis;SarcoidosisDrug: Prednisone or Prednisolone;Drug: MethotrexateOttawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR)Recruiting18 YearsN/AAll194Phase 3United States;Canada;Japan;United Kingdom
47NCT03746847
(ClinicalTrials.gov)
December 1, 201829/10/2018PET Imaging in Patients With Suspected Cardiac SarcoidosisSomatostatin Receptor Imaging in Patients With Suspected Cardiac SarcoidosisCardiac SarcoidosisDrug: Gallium-68 DOTATATEUniversity of PennsylvaniaAdvanced Accelerator ApplicationsCompleted18 YearsN/AAll20United States
48NCT03602976
(ClinicalTrials.gov)
August 20, 201819/7/2018Ursodeoxycholic Acid (UDCA) for Hepatic SarcoidosisA Single-center, Open Label, Cross-over Study on the Effects of Ursodeoxycholic Acid (UDCA) in Patients With Hepatic SarcoidosisHepatic Sarcoidosis, Elevated Alkaline PhosphataseDrug: Ursodeoxycholic AcidEthan WeinbergAmerican Association for the Study of Liver Diseases;Exalenz Bioscience LTD.Completed18 YearsN/AAll6Phase 2United States
49NCT03549598
(ClinicalTrials.gov)
July 20, 201825/5/2018d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosisd68Ga-DOTATATE PET/CT Assessment of Cardiac SarcoidosisCardiac SarcoidosisDrug: 68Ga-DOTATATE PET/CT;Drug: 18FDG PET/CT scan;Drug: 13NH3 PET/CT scanMayo ClinicNULLCompleted18 YearsN/AAll15Phase 4United States
50NCT03528070
(ClinicalTrials.gov)
May 201819/4/2018A Clinical Study of Tranilast in the Treatment of SarcoidosisA Clinical Study of Tranilast in the Treatment of SarcoidosisSarcoidosisDrug: TranilastThe First Affiliated Hospital with Nanjing Medical UniversityNULLUnknown status18 YearsN/AAll56Early Phase 1NULL
51NCT03320070
(ClinicalTrials.gov)
February 21, 201820/10/2017Acthar Gel in Participants With Pulmonary SarcoidosisA Multicenter, Randomized, Double Blind, Placebo Controlled Exploratory Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary SarcoidosisSarcoidosis, PulmonaryDrug: Acthar Gel;Drug: PlaceboMallinckrodtNULLCompleted18 Years90 YearsAll55Phase 4United States
52NCT03705884
(ClinicalTrials.gov)
January 1, 20188/8/2018PET/MR Imaging In Patients With Cardiac SarcoidosisMolecular Imaging in Cardiovascular Disease Using Hybrid Positron Emission Tomography/Magnetic Resonance Imaging (PET/MR): Cardiac SarcoidosisCardiac SarcoidosisOther: 18F-FDG;Drug: PrednisoloneUniversity of EdinburghNULLUnknown status40 YearsN/AAll40N/AUnited Kingdom
53NCT03324503
(ClinicalTrials.gov)
December 8, 201712/10/2017A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary SarcoidosisA Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary SarcoidosisSarcoidosis, PulmonaryDrug: Glucocorticoid (prednisone or prednisolone)CelgeneNULLCompleted18 Years65 YearsAll8N/AUnited States;Netherlands;United Kingdom
54NCT03260556
(ClinicalTrials.gov)
September 27, 201722/8/2017Pirfenidone for Progressive Fibrotic SarcoidosisPirfenidone for Progressive Fibrotic SarcoidosisSarcoidosis, PulmonaryDrug: Pirfenidone;Drug: PlacebosUniversity of CincinnatiRoyal Brompton & Harefield NHS Foundation TrustRecruiting18 Years90 YearsAll60Phase 4United States
55NCT03103490
(ClinicalTrials.gov)
August 2, 201710/3/201718F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or InflammationCardiac Sarcoidosis;Myocardial InflammationDrug: 18F-FSPGStanford UniversityGE HealthcareRecruiting18 YearsN/AAll50Phase 2United States
56EUCTR2016-003360-39-DE
(EUCTR)
27/06/201711/04/2017Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosisSafety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis - ABASARC Steroid-refractory Sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ORENCIAUniversitätsklinikum FreiburgNULLNot RecruitingFemale: yes
Male: yes
30Phase 2Germany
57JPRN-UMIN000025936
2017/06/1220/02/2017Japanese AntibaCterial drug maNagemEnt for cardiac Sarcoidosis TrialJapanese AntibaCterial drug maNagemEnt for cardiac Sarcoidosis Trial - J-ACNES Cardiac sarcoidosiscombination therapy group:
Prednisolone; Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5mg.
Antimicrobial agent; Clarithromycin start from 400mg/day for 24weeks. Doxycycline start 100mg/day for 22 weeks after 2 months of clarithromycin therapy.

Prednisolone; Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5mg.
National cerebral and cardiovascular centerNULLComplete: follow-up continuing20years-oldNot applicableMale and Female80Not selectedJapan
58NCT03402308
(ClinicalTrials.gov)
June 1, 201710/1/2018Effect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a RCTEffect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a Randomized, Double-blinded, Placebo-controlled TrialMuscular SarcoidosisDietary Supplement: Schisandra chinensis extract;Dietary Supplement: PlaceboPusan National University Yangsan HospitalNULLCompleted50 YearsN/AAll54N/AKorea, Republic of
59JPRN-jRCTs031180301
01/05/201715/03/2019Antibacterial therapy for severe sarcoid uveitisStudy of antibacterial therapy for severe uveitis by sarcoidosis Severe uveitis by sarcoidosis
Other eyes and adnexal disease
Ordinary steroid medication with Clarithromycin and minomycinTakase HiroshiNULLComplete20age80ageBoth10Phase 1-2Japan
60NCT03265405
(ClinicalTrials.gov)
April 1, 201723/8/2017Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of SarcoidosisEfficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled TrialSarcoidosisDrug: Low dose prednisolone;Drug: Medium dose prednisolonePostgraduate Institute of Medical Education and ResearchNULLCompleted18 YearsN/AAll86Phase 4India
61NCT03259282
(ClinicalTrials.gov)
March 7, 201721/8/2017Gammaglobulins Level is Predictive Factor of Evolution in SarcoidosisGammaglobulins Level is Predictive Factor of Evolution in SarcoidosisSarcoidosisBiological: Analysis of gamma globulinRennes University HospitalNULLCompletedN/AN/AAll78France
62NCT03048097
(ClinicalTrials.gov)
February 1, 20172/2/2017Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac SarcoidosisSarcoidosisDrug: Fluorodeoxyglucose;Drug: Rubidium;Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion ImagingYale UniversityNULLCompleted18 YearsN/AAll15Early Phase 1United States
63NCT02888080
(ClinicalTrials.gov)
December 19, 201616/8/2016Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary SarcoidosisA Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary SarcoidosisPulmonary SarcoidosisDrug: ACZ885;Drug: PlaceboNovartis PharmaceuticalsNULLCompleted18 Years80 YearsAll40Phase 2United States;Germany;Netherlands
64JPRN-jRCTs041180111
16/12/201619/03/2019Estimated by FDG PET/CT in Myocardial SarcoidosisOptimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - OMT-CS study Cardiac sarcoidosis
Cardiac sarcoidosis
After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasing over 70%, PSL was prescribed 5mg/day for more 6 months. If TLG is decreasing under 70%, arm A: PSL was prescribed 30mg/day and diminishing PSL 5mg per month for more 6 months arm B: MTX (6mg/week) and folic acid (5mg/week) was prescribed for more 6 monthsMurohara ToyoakiNULLComplete>= 20age oldNot applicableBoth85Phase 3Japan
65EUCTR2016-002160-14-NL
(EUCTR)
22/11/201625/10/2016Octreotide PET/CT scan for the imaging of disease activity in neurologic and cardiac sarcoidosis.68Ga-DOTA-NOC PET/CT for the imaging of disease activity in neurologic and cardiac sarcoidosis. - SCAN-GO Trial Sarcoidosis.;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: Gallium-68-DOTA-N-Octreotide
Product Code: Ga-68-DOTA-NOC
INN or Proposed INN: Ga-68-DOTA-NOC
Other descriptive name: DOTANOC
St. Antonius HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Netherlands
66NCT02643732
(ClinicalTrials.gov)
November 201623/12/2015Fatigue in Sarcoidosis - Treatment With MethylphenidateFatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using MethylphenidateSarcoidosis;FatigueDrug: Methylphenidate (overencapsulated);Drug: Placebo (Over-encapsulated tablet)University of East AngliaClinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)Recruiting18 YearsN/AAll30N/AUnited Kingdom
67EUCTR2016-001255-49-NL
(EUCTR)
18/10/201620/07/2016Study of efficacy, safety and tolerability of ACZ885 (Canakinumab) in patients with pulmonary sarcoidosisA multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosis Pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ILARIS
Product Code: ACZ885
INN or Proposed INN: canakinumab
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
38Phase 2United States;Germany;Netherlands
68JPRN-UMIN000022996
2016/10/0804/07/2016Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial SarcoidosisOptimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - Optimal Medical Therapy in Myocardial Sarcoidosis Myocardial sarcoidosismediacl therapy with methotrexate
medical therapy with steroid
The Department of Cardiology, Nagoya University Graduate School of MedicineNULLRecruiting20years-old90years-oldMale and Female50Not selectedJapan
69EUCTR2016-001255-49-DE
(EUCTR)
15/08/201611/07/2016Study of efficacy, safety and tolerability of ACZ885 (Canakinumab) in patients with pulmonary sarcoidosisA multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosis Pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ILARIS
Product Code: ACZ885
INN or Proposed INN: canakinumab
Novartis Pharma Services AGNULLNot Recruiting Female: yes
Male: yes
38 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Netherlands;Germany
70EUCTR2016-000342-60-GB
(EUCTR)
21/06/201606/02/2019Fatigue and Sarcoidosis: Treatment with MethylphenidateFatigue in Sarcoidosis - A feasibility study investigating the treatment of fatigue in stable sarcoidosis patients using methylphenidate - Fatigue in Sarcoidosis: Treatment with Methylphenidate Sarcoidosis-associated fatigue (Patients with stable sarcoidosis and chronic fatigue)
MedDRA version: 20.1;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Methylphenidate
Product Name: Methylphenidate 10mg tablets
Product Code: NA
INN or Proposed INN: Methylphenidate
Other descriptive name: None
Norfolk and Norwich University HospitalNULLNot Recruiting Female: yes
Male: yes
30 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
71NCT02812849
(ClinicalTrials.gov)
June 201622/6/2016Somatostatin Receptor Imaging in Cardiac SarcoidosisSomatostatin Receptor Imaging in Cardiac SarcoidosisCardiac SarcoidosisDrug: Cu-64 DOTATATERigshospitalet, DenmarkNULLWithdrawn18 YearsN/AAll0Denmark
72NCT02824419
(ClinicalTrials.gov)
May 201627/5/2016Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary SarcoidosisImaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary SarcoidosisPulmonary SarcoidosisDrug: Methionine;Drug: DOTANOCTurku University HospitalNULLRecruiting18 YearsN/ABoth10Phase 2/Phase 3Finland
73NCT02298491
(ClinicalTrials.gov)
May 201614/11/2014CNS Sarcoidosis and Acthar GelClinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar GelCNS SarcoidosisDrug: H.P. Acthar GelUniversity of Maryland, BaltimoreMallinckrodtCompletedN/AN/AAll4Phase 4United States
74EUCTR2015-001815-11-FI
(EUCTR)
19/04/201629/12/2015PET imaging of pulmonary sarcoidosisImaging of active granulomas with [18F]FDG and selected inflammatory PET tracers in pulmonary sarcoidosis Pulmonary sarcoidosis with active garnulomas in the lungs. The diagnosis is based on the clinical evidence or biopsy.
MedDRA version: 18.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-fluorodeoxyglucose
Product Code: FDG
INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE
Product Name: C11-methionine
INN or Proposed INN: L-methionine
Other descriptive name: L-METHIONINE ([11C]METHYL)
Product Name: 68Ga-DOTANOC
INN or Proposed INN: DOTANOC
Other descriptive name: DOTANOC
Turku PET CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Finland
75NCT02546388
(ClinicalTrials.gov)
October 20159/9/2015Somatostatin Receptor Imaging in Patients With Suspected Cardiac SarcoidosisSomatostatin Receptor Imaging in Patients With Suspected Cardiac SarcoidosisSarcoidosisDrug: Indium-111 Pentreotide;Drug: Gallium-68 DOTATATEMarcelo F. Di Carli, MD, FACCMallinckrodtCompleted18 Years90 YearsAll17N/AUnited States
76ChiCTR-DCD-15007110
2015-09-012015-09-20The clinical application of new methods for differential diagnosis of sarcoidosis andsputum negative tuberculosisThe clinical application of new methods for differential diagnosis of sarcoidosis andsputum negative tuberculosis sarcoidosis andsputum negative tuberculosisGold Standard:;Index test:;Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of MedicineNULLRecruiting18BothTarget condition:0;Difficult condition:0China
77EUCTR2013-005333-21-NL
(EUCTR)
30/06/201508/01/2015Study of efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosisA multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis Pulmonary sarcoidosis
MedDRA version: 17.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ILARIS
Product Name: Canakinumab
Product Code: ACZ885
INN or Proposed INN: Canakinumab
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
90United States;Netherlands
78EUCTR2014-002224-26-NL
(EUCTR)
07/05/201503/02/2015Infliximab dosing based on blood concentrations in patients with sarcoidosis: smart dosingA new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment - Concentration guided dosing of infliximab in sarcoidosis Sarcoidosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Remicade
Product Name: Remicade
St. Antonius HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
79NCT02625558
(ClinicalTrials.gov)
April 201526/5/2015Riociguat for Sarcoidosis Associated Pulmonary HypertensionA Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary HypertensionSarcoidosisDrug: Riociguat;Drug: PlaceboUniversity of CincinnatiNULLRecruiting18 YearsN/ABoth60Phase 4United States
80NCT02348905
(ClinicalTrials.gov)
March 201520/6/2014ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label TrialACTHAR Gel for Cutaneous Sarcoidosis: An Open Label TrialSarcoidosis;Cutaneous SarcoidosisDrug: ACTHAR Gel 40 units twice weekly;Drug: ACTHAR Gel 80 units twice weekly.Albany Medical CollegeNULLNot yet recruiting18 YearsN/ABoth10Phase 2/Phase 3United States
81NCT02155803
(ClinicalTrials.gov)
February 201530/5/2014ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot StudyACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot StudySarcoidosis;Hypercalcemia Due to SarcoidosisDrug: ACTHAR Gel (adrenocorticotropic hormone)Albany Medical CollegeNULLNot yet recruiting18 YearsN/ABoth10Phase 2/Phase 3United States
82NCT02265874
(ClinicalTrials.gov)
January 12, 201510/10/2014Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot StudyNicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot StudySarcoidosisDrug: Habitrol;Drug: Placebo to HabitrolOhio State UniversityThe Cleveland ClinicCompleted18 Years75 YearsAll57Phase 1/Phase 2United States
83NCT02192489
(ClinicalTrials.gov)
November 1, 201415/7/2014A Phase 2 Study With CC-220 in Skin SarcoidosisA Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous SarcoidosisSarcoidosisDrug: CC-220 0.3 mg Daily;Drug: CC-220 0.6mg Daily;Drug: PlaceboCelgeneNULLWithdrawn18 YearsN/AAll0Phase 2NULL
84EUCTR2013-005376-17-NL
(EUCTR)
20/06/201427/02/2014Sandostatin therapy in sarcoidosisSandostatin therapy in sarcoidosis - SST in SA Sarcoidosis
MedDRA version: 16.1;Level: HLGT;Classification code 10003816;Term: Autoimmune disorders;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Sandostatin LAR
INN or Proposed INN: OCTREOTIDE
Other descriptive name: octreotide LAR / Sandostatin LAR (LAR=long acting release)
Erasmus Medical CenterNULLNot RecruitingFemale: yes
Male: yes
Netherlands
85NCT02188017
(ClinicalTrials.gov)
June 201424/4/2014Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS)Sarcoidosis;Pulmonary SarcoidosisDrug: Acthar gelUniversity of CincinnatiMallinckrodtRecruiting18 Years90 YearsBoth20Phase 4United States
86NCT02036970
(ClinicalTrials.gov)
May 201413/1/2014Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIATA Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary HypertensionPulmonary Arterial Hypertension;Pulmonary Hypertension;Interstitial Lung Disease;Idiopathic Interstitial Pneumonia;Idiopathic Pulmonary Fibrosis;Sarcoidosis;Respiratory Bronchiolitis Associated Interstitial Lung Disease;Desquamative Interstitial Pneumonia;Cryptogenic Organizing Pneumonia;Acute Interstitial Pneumonitis;Idiopathic Lymphoid Interstitial Pneumonia;Idiopathic Pleuroparenchymal FibroelastosisDrug: Bardoxolone methyl;Drug: PlaceboReata Pharmaceuticals, Inc.NULLCompleted18 Years75 YearsAll166Phase 2United States;Germany;Spain;United Kingdom
87NCT01955824
(ClinicalTrials.gov)
May 201425/9/2013A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible BronchoscopyA RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPYLung Cancer;Tuberculosis;Sarcoidosis;Interstitial Lung DiseaseDrug: 1% lignocaine;Drug: 2% lignocainePostgraduate Institute of Medical Education and ResearchNULLCompleted12 Years80 YearsBoth500Phase 2/Phase 3India
88JPRN-UMIN000013831
2014/04/3030/04/2014Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitationEffect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation - Effect of inhaled corticosteroid therapy on pulmonary sarcoidosis Pulmonary sarcoidosis patients who revealed airflow limitation in peak flow tests, increased respiratory resistance in IOS, or increased WA% in HRCT.inhaled ciclesonide (400maicrogram, twice daily, for three months)Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, JapanNULLRecruiting20years-old80years-oldMale and Female40Not selectedJapan
89NCT01210677
(ClinicalTrials.gov)
April 201427/9/2010Cardiac Sarcoidosis Response To Steroids TrialCArdiac Sarcoidosis Response TO steRoids (CASTOR) TrialCardiac Sarcoidosis;SarcoidosisDrug: PrednisoneOttawa Heart Institute Research CorporationNULLWithdrawn18 YearsN/ABoth0Phase 4Canada
90NCT02024555
(ClinicalTrials.gov)
March 201426/12/2013Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary SarcoidosisInvestigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled TrialSarcoidosis; Antimycobacterial TherapyDrug: Levofloxacin;Drug: Ethambutol;Drug: Azithromycin;Drug: Rifampin;Drug: PlaceboVanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed18 YearsN/AAll97Phase 2United States
91NCT02134717
(ClinicalTrials.gov)
January 201430/4/2014Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis ImmunophenotypesAn Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With SarcoidosisSarcoidosisDrug: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks;Procedure: Bronchoscopy with bronchoalveolar lavage;Procedure: venipunctures;Procedure: Skin biopsyKevin F. GibsonUniversity of PittsburghTerminated18 Years80 YearsAll3N/AUnited States
92NCT02039687
(ClinicalTrials.gov)
January 201416/1/2014Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisA Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisNeuropathy of SarcoidosisDrug: ARA 290;Other: PlaceboAraim Pharmaceuticals, Inc.NULLCompleted18 Years70 YearsAll64Phase 2United States;Netherlands
93EUCTR2013-003016-45-NL
(EUCTR)
11/09/201315/08/2013study the safety and effects of different doses of ARA 290 administered subcutaneously on the corneal nerve fiber density and symptoms of neuropathic pain in sarcoidosis patients.A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis - DOSARA small fiber neuropathy;Therapeutic area: Body processes [G] - Biological Phenomena [G16]Product Name: ARA 290
Product Code: ARA 290
INN or Proposed INN: ARA 290
Araim PharmaceuticalsNULLNot RecruitingFemale: yes
Male: yes
64Phase 2United States;Netherlands
94NCT01920919
(ClinicalTrials.gov)
June 20137/8/2013Low-dose Dexamethasone in Newly Diagnosed Pulmonary SarcoidosisSarcoidosisDrug: Dexamethasone;Drug: PlaceboSt. Antonius HospitalNULLRecruiting18 Years60 YearsBoth76Phase 3Netherlands
95EUCTR2013-000242-18-NL
(EUCTR)
23/05/201311/04/2013Low dose dexamethasone in newly diagnosed sarcoidosisLow dose dexamethasone in newly diagnosed sarcoidosis - (DEXSAR) Trial Patients with newly diagnosed, pulmonary sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Dexamethasone 0,5mg
Product Name: Dexamethasone
INN or Proposed INN: DEXAMETHASONE
Other descriptive name: Dexamethasone
NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
96NCT01830959
(ClinicalTrials.gov)
April 201310/4/2013Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)SarcoidosisDrug: Roflumilast;Drug: PlaceboUniversity of CincinnatiThe Cleveland Clinic;University of Pittsburgh;University of Illinois at Chicago;Henry Ford Health System;Albany Medical CollegeActive, not recruiting18 Years70 YearsBoth50Phase 4United States
97NCT01732211
(ClinicalTrials.gov)
March 15, 201319/11/2012A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary SarcoidosisA PHASE 2 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, 20-WEEK SAFETY, TOLERABILITY, AND EFFICACY STUDY OF PD 0360324 IN ADULT SUBJECTS WITH CHRONIC PULMONARY SARCOIDOSISPulmonary SarcoidosisBiological: PD 0360324;Other: Normal Saline for injectionPfizerNULLTerminated21 Years75 YearsAll1Phase 2United States
98NCT01652417
(ClinicalTrials.gov)
October 201216/5/2012Treatment of Renal Sarcoidosis by Methylprednisolone BolusRandomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal SarcoidosisRenal SarcoidosisDrug: methylprednisolone bolus IV 15 mg/kg/d for 3 days.Assistance Publique - Hôpitaux de ParisNULLTerminated18 YearsN/ABoth40N/AFrance
99NCT01687517
(ClinicalTrials.gov)
October 201214/9/2012Efficacy and Safety of Influenza Vaccine During SarcoidosisDetermination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis.Sarcoidosis;Influenza VaccineDrug: Seasonal influenza vaccine available for the 2012-2013 vaccine campaignAssistance Publique - Hôpitaux de ParisNULLCompleted18 Years65 YearsBoth190Phase 3France
100ChiCTR-IOR-15005953
2012-01-012015-01-11The effects of corticosteroid treatment on asymptomatic sarcoidosisThe effects of corticosteroid treatment on asymptomatic sarcoidosis SarcoidosisCorticosteroid-treated group :prednisolone ;Placebo:Placebo;The First Affiliated Hospital, Guangzhou Medical UniversityNULLCompleted1876BothCorticosteroid-treated group :64;Placebo:63;NULL
101JPRN-UMIN000008813
2012/01/0101/09/2012Efficacy of antibiotic prophylaxis on postbronchoscopy fever after endobronchial ultrasound-guided transbronchial needle biopsyEfficacy of antibiotic prophylaxis on postbronchoscopy fever after endobronchial ultrasound-guided transbronchial needle biopsy - Antibiotic prophylaxis after EBUS-TBNA primary lung cancer, sarcoidosis, malignant lymphoma, metastatic lung tumor,mediastinal tumor, etc.AMPC/CVA+ABPC/SBT.
Control.
Respiratory medicine, Juntendo university.NULLComplete: follow-up complete20years-old85years-oldMale and Female500Not selectedJapan
102EUCTR2011-003630-13-NL
(EUCTR)
22/11/201107/11/2011Tracer for the imaging of disease activity in sarcoidosis in the lung99mTc labelled anti-TNF-alpha for the imaging of disease activity in pulmonary sarcoidosis - TISS Pulmonary sarcoidosis
MedDRA version: 17.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: 99mTc-Infliximab
Product Code: not applicable
INN or Proposed INN: not applicable
Other descriptive name: 99m technetium infliximab
Sint Antonius HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
103NCT01587001
(ClinicalTrials.gov)
November 201110/1/2012The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary SarcoidosisThe Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary SarcoidosisPulmonary SarcoidosisDietary Supplement: N-acetyl-cysteine;Drug: PlaceboNational Jewish HealthAmerican Thoracic SocietyCompleted18 Years80 YearsAll17N/AUnited States
104NCT01440192
(ClinicalTrials.gov)
September 201119/9/2011Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary SarcoidosisA Phase 1B, Multi-Center, Open-Label, Single Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placental-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis.SarcoidosisStage 2 Pulmonary Sarcoidosis;Stage 3 Pulmonary SarcoidosisBiological: PDA001 (cenplacel-L)Celularity IncorporatedNULLTerminated18 Years75 YearsAll4Phase 1United States
105NCT01324999
(ClinicalTrials.gov)
March 201124/3/2011Tadalafil for Sarcoidosis Associated Pulmonary HypertensionTadalafil for Sarcoidosis Associated Pulmonary HypertensionPulmonary HypertensionDrug: TadalafilUniversity of North Carolina, Chapel HillEli Lilly and Company;United Therapeutics;University of CincinnatiCompleted18 YearsN/AAll12Phase 2/Phase 3United States
106JPRN-UMIN000004267
2010/10/0101/10/2010PET/CT finding of cardiac sarcoidosisPET/CT finding of cardiac sarcoidosis - PET/CT finding of cardiac sarcoidosis sarcoidosisGive heparin Na before 18F-FDG PET/CT in the diagnosis of cardial sarcoidosis.Tokushima University HospitalNULLPendingNot applicableNot applicableMale and Female30Not selectedJapan
107NCT03621553
(ClinicalTrials.gov)
July 1, 201017/7/2018Vitamin D Homeostasis in SarcoidosisVitamin D Homeostasis in SarcoidosisSarcoidosis;Vitamin D InsufficiencyDrug: Ergocalciferol;Drug: Placebo;Drug: Calcium Citrate with Vitamin D2University of Texas Southwestern Medical CenterNULLActive, not recruiting21 YearsN/AAll90Phase 4United States
108NCT01169038
(ClinicalTrials.gov)
July 201022/7/2010Investigation of the Efficacy of Antibiotics on Pulmonary SarcoidosisInvestigation of the Efficacy of Antibiotics on Pulmonary SarcoidosisPulmonary Sarcoidosis;Lung FunctionDrug: levaquin; ethambutol; rifampin and azithromycin.Vanderbilt UniversityNULLCompleted18 Years75 YearsAll15Phase 1United States
109JPRN-UMIN000006533
2010/04/0130/10/2011Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effectsDetecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects - Detecting sympathetic denervation and regional myocardial inflammation in patients with cardiac involvement sarcoidosis (CANVAS study) sarcoidosisAll patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 11C HED PET/CT,18F FDG PET/CT, 15O-PET water, MIBG, 12 leads ECG, AECG , SAECG and echocardiogram (Echo) before starting corticosteroid therapy and repeat study at 4 weeks after starting corticosteroid therapy. These patients will also have reevaluation 6 to 12 month after the second evaluations.
Sarcoidosis without cardiac involvement will undergo steroid treatment will also repeat the same measurements 4 weeks after the treatment.
Cardiac sarcoidosis but will not have steroid treatment will also repeat the same measurements 12 months later. Sarcoidosis patients without steroid treatment will also repeat the same measurements 12 months later.
Cardiac sarcoidosis with steroid treatment.

Cardiac sarcoidosis without steroid treatment.
arcoidosis without cardiac involvement who will have steroid treatement.
Sarcoidosis without cardiac involvement who will not have steroid treatement.
Normal control.
Hokkaido University Graduate School of Medicine,NULLRecruitingNot applicableNot applicableMale and Female50Not applicableJapan
110NCT01074554
(ClinicalTrials.gov)
February 20108/2/2010Trial of Antimycobacterial Therapy in SarcoidosisPhase I/II Study of the Effects of Antibiotics on Sarcoidosis PathogenesisSarcoidosisDrug: Antibiotic Regimen;Drug: Placebo RegimenVanderbilt UniversityNULLCompleted18 YearsN/AAll30Phase 1/Phase 2United States
111EUCTR2009-010714-30-IT
(EUCTR)
18/01/201011/12/2009A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis - ND Chronic sarcoidosis
MedDRA version: 9.1;Level: LLT;Classification code 10039486
Product Name: Ustekinumab
Product Code: CNTO1275
Product Name: Golimumab
Product Code: CNTO148
CENTOCORNULLNot RecruitingFemale: yes
Male: yes
180Phase 2United Kingdom;Germany;Netherlands;Denmark;Belgium;France;Italy
112EUCTR2009-010714-30-NL
(EUCTR)
22/12/200903/02/2011A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis - Chronic sarcoidosis
MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: human anti-IL 12/23 monoclonal antibody
Centocor BVNULLNot RecruitingFemale: yes
Male: yes
180Phase 2United Kingdom;Germany;Netherlands;Denmark;Belgium;France;Italy
113EUCTR2009-010714-30-FR
(EUCTR)
10/11/200915/10/2009A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis Chronic sarcoidosis
MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: human anti-IL 12/23 monoclonal antibody
Centocor BVNULLNot RecruitingFemale: yes
Male: yes
180Phase 2France;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom
114NCT00955279
(ClinicalTrials.gov)
November 20096/8/2009A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With SarcoidosisA Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic SarcoidosisSarcoidosisDrug: Placebo;Drug: Golimumab;Drug: UstekinumabCentocor, Inc.NULLCompleted18 Years85 YearsAll173Phase 2United States;Belgium;Denmark;France;Germany;Netherlands;Norway;Romania;United Kingdom;Sweden
115EUCTR2009-010714-30-DE
(EUCTR)
23/10/200908/07/2009A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis Chronic sarcoidosis
MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: human anti-IL 12/23 monoclonal antibody
Janssen Biologics B.V.NULLNot RecruitingFemale: yes
Male: yes
180Phase 2France;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom
116EUCTR2009-010714-30-DK
(EUCTR)
12/10/200917/08/2009A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients with SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis Chronic sarcoidosis
MedDRA version: 14.0;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: human anti-IL 12/23 monoclonal antibody
Janssen Biologics B.V.NULLNot RecruitingFemale: yes
Male: yes
180Phase 2France;United States;Belgium;Romania;Denmark;Netherlands;Germany;Italy;United Kingdom
117EUCTR2009-010714-30-BE
(EUCTR)
28/09/200908/07/2009A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients with SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis Chronic sarcoidosis
MedDRA version: 13.1;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: Human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: Human anti-IL 12/23 monoclonal antibody
Janssen Biologics B.V.NULLNot RecruitingFemale: yes
Male: yes
180Phase 2France;United States;Belgium;Denmark;Germany;Norway;Netherlands;Italy;United Kingdom
118EUCTR2009-010714-30-GB
(EUCTR)
14/09/200920/07/2009A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis Chronic sarcoidosis
MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: human anti-IL 12/23 monoclonal antibody
Janssen Biologics B.V.NULLNot Recruiting Female: yes
Male: yes
180 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom
119NCT00918554
(ClinicalTrials.gov)
September 20099/6/2009Efficacy Study of Methotrexate to Treat Sarcoid-associated UveitisCorticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATESarcoid-associated Uveitis;Ocular Sarcoidosis;Macular EdemaDrug: Methotrexate;Drug: PlaceboAssistance Publique - Hôpitaux de ParisNULLTerminated18 YearsN/ABoth7Phase 4France
120NCT00855205
(ClinicalTrials.gov)
July 20093/3/2009Rituximab for Pulmonary SarcoidosisRituximab as a Novel Therapy in Refractory Sarcoidosis: A Prospective Open-SarcoidosisDrug: RituximabUniversity of CincinnatiUniversity of ChicagoCompleted18 YearsN/ABoth10Phase 2United States
121NCT00731757
(ClinicalTrials.gov)
May 20096/8/2008Efficacy Study of Humira in the Treatment of Cutaneous SarcoidosisA Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous SarcoidosisSarcoidosis;Cutaneous SarcoidosisDrug: HumiraWright State UniversityStanford UniversityWithdrawn18 YearsN/AAll0Phase 2United States
122NCT00926627
(ClinicalTrials.gov)
April 200922/6/2009Safety and Efficacy Study of Bosentan in Progressive Pulmonary SarcoidosisA Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary SarcoidosisSarcoidosis;Pulmonary HypertensionDrug: bosentan;Drug: placeboDaniel DobererNULLTerminated18 Years70 YearsBoth32Phase 2Austria
123NCT02200146
(ClinicalTrials.gov)
March 200910/7/2014Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial.Pulmonary SarcoidosisDrug: Prednisone;Drug: Hydroxychloroquine + PrednisoneUniversity of Milano BicoccaAgenzia Italiana del FarmacoCompleted18 Years70 YearsBoth94Phase 3Italy
124NCT01245036
(ClinicalTrials.gov)
January 200915/11/2010Efficacy of Antituberculous Therapy in Management of SarcoidosisRifampicin and Isoniazid Along With Prednisolone Compared to Prednisolone Alone in Treatment of Sarcoidosis: a Pilot Randomized Controlled TrialSarcoidosis;TuberculosisDrug: Antituberculous therapy along with steroidsPostgraduate Institute of Medical Education and ResearchNULLCompleted15 Years75 YearsBoth100N/AIndia
125NCT00828828
(ClinicalTrials.gov)
December 200823/1/2009Antibody Response to Influenza Vaccine in Patients With SarcoidosisControlled Trial of Serologic Efficacy of Influenza Vaccine in Patients With SarcoidosisPulmonary SarcoidosisBiological: Influenza VaccineShahid Beheshti Medical UniversityNULLCompleted20 Years60 YearsBoth49Iran, Islamic Republic of
126NCT00851929
(ClinicalTrials.gov)
November 200824/2/2009Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary HypertensionAmbrisentan (Letairis) for Sarcoidosis Associated Pulmonary HypertensionSarcoidosis;Pulmonary HypertensionDrug: AmbrisentanMedical University of South CarolinaGilead SciencesCompleted18 Years99 YearsAll16Phase 2/Phase 3United States
127NCT00794274
(ClinicalTrials.gov)
November 200819/11/2008The Efficacy and Safety of CC-10004 in Chronic Cutaneous SarcoidosisThe Efficacy and Safety of CC-10004 in Chronic Cutaneous SarcoidosisSarcoidosis;Cutaneous SarcoidosisDrug: CC-100004University of CincinnatiCelgene Corporation;Medical University of South CarolinaCompleted18 Years80 YearsBoth15Phase 2/Phase 3United States
128NCT00739960
(ClinicalTrials.gov)
August 200820/8/2008Safety Study of Abatacept to Treat Refractory SarcoidosisSarcoidosis, Trial of Abatacept in Refractory Disease (STAR). A Prospective Open-Label Trial of Abatacept in Progressive SarcoidosisSarcoidosisDrug: AbataceptUniversity of ChicagoBristol-Myers SquibbTerminated18 YearsN/AAll1Phase 2United States
129NCT00701207
(ClinicalTrials.gov)
July 200817/6/2008Study of Nicotine Patches in Patients With SarcoidosisModulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine ReceptorsPulmonary SarcoidosisDrug: nicotine patchElliott Crouser MDAmerican Thoracic SocietyCompleted18 YearsN/AAll64Early Phase 1United States
130EUCTR2008-001340-39-IT
(EUCTR)
30/06/200813/06/2008Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSASHydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS Pulmonary SarcoidosisTrade Name: PLAQUENIL*25CPR RIV 200MG
INN or Proposed INN: Hydroxychloroquine
Trade Name: DELTACORTENE*10CPR 25MG
INN or Proposed INN: Prednisone
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
131EUCTR2007-005117-18-AT
(EUCTR)
03/04/200804/03/2008Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSACSafety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSAC Progressive pulmonary sarcoidosis
MedDRA version: 9.1;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis
Trade Name: Tracleer
Product Name: Bosentan
Medical University of Vienna, Department of Clinical PharmacologyNULLNot RecruitingFemale: yes
Male: yes
Austria
132NCT00581607
(ClinicalTrials.gov)
April 200826/12/2007Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary HypertensionDouble Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary HypertensionSarcoidosis;Pulmonary Arterial HypertensionDrug: Bosentan;Drug: PlaceboUniversity of CincinnatiActelionCompleted18 YearsN/ABoth43Phase 2/Phase 3United States
133NCT02829853
(ClinicalTrials.gov)
January 20084/7/2016Clinical and Genetic Study of Familial Sarcoidosis (SARCFAM)Clinical and Genetic Study of Familial Sarcoidosis (SARCFAM)SarcoidosisGenetic: Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCINGHospices Civils de LyonNULLRecruiting8 Years80 YearsBoth800N/AFrance
134NCT00555347
(ClinicalTrials.gov)
October 20077/11/2007Use of Armodafinil for Fatigue in SarcoidosisUse of Armodafinil (R-modafinil) for Fatigue in SarcoidosisSarcoidosis;Fatigue;SleepinessDrug: Armodafinil;Drug: PlaceboUniversity of CincinnatiCephalonCompleted18 YearsN/ABoth20Phase 2/Phase 3United States
135NCT00690911
(ClinicalTrials.gov)
August 20072/6/2008Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous SarcoidosisA Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis (HUM 04-36)SarcoidosisDrug: adalimumabWake Forest UniversityNULLWithdrawn18 YearsN/AAll0Phase 2United States
136EUCTR2006-005361-19-GB
(EUCTR)
09/03/200717/12/2006Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosisEvaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosis Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstructive Pulmonary disease and Sarcoid. Once developed it may go on to cause right heart failure and severe breathlessness and eventually death. We believe that the use of bosentan may lower the pulmonary hypertension and improve symptoms.
MedDRA version: 8.1;Level: LLT;Classification code 10037400;Term: Pulmonary hypertension
Trade Name: Tracleer
Product Name: tracleer
INN or Proposed INN: Bosentan monohydrate
St Georges HospitalNULLNot Recruiting Female: yes
Male: yes
45 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom
137NCT00403650
(ClinicalTrials.gov)
November 200624/11/2006Inhaled Iloprost for Sarcoidosis-associated Pulmonary HypertensionInhaled Iloprost for Sarcoidosis Associated Pulmonary HypertensionSarcoidosis;Pulmonary Arterial HypertensionDrug: IloprostUniversity of CincinnatiNULLCompleted18 Years90 YearsBoth20Phase 4United States
138NCT00274352
(ClinicalTrials.gov)
September 20066/1/2006A Study of Adalimumab to Treat Sarcoidosis of the SkinA Double-Blind, Randomized, Placebo-Controlled Study of Adalimumab in the Treatment of Cutaneous SarcoidosisSarcoidosisDrug: adalimumabPariser, Robert J., M.D.Abbott;Virginia Clinical Research, Inc.Completed18 Years89 YearsBoth16Phase 2United States
139NCT00361387
(ClinicalTrials.gov)
June 20067/8/2006Use of Focalin for Fatigue in SarcoidosisRandomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects.SarcoidosisDrug: d-methylphenidateUniversity of CincinnatiNULLCompleted18 YearsN/ABoth12Phase 4United States
140EUCTR2006-001816-56-DK
(EUCTR)
11/05/200628/04/2006Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? - KOMPLETCan PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? - KOMPLET sarcoidosisTrade Name: Humira
Product Name: Humira
RigshospitaletNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
10Phase 2Denmark
141NCT00311246
(ClinicalTrials.gov)
April 20063/4/2006Trial of Adalimumab in Progressive SarcoidosisA Prospective Open-Label Trial of Adalimumab in Progressive SarcoidosisSarcoidosisDrug: AdalimumabUniversity of ChicagoAbbottTerminated18 Years85 YearsAll11Phase 2United States
142NCT00279708
(ClinicalTrials.gov)
January 200618/1/2006Atorvastatin to Treat Pulmonary SarcoidosisAtorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled TrialSarcoidosis, PulmonaryDrug: Atorvastatin;Other: Placebo Oral TabletNational Heart, Lung, and Blood Institute (NHLBI)NULLCompleted18 Years70 YearsAll55Phase 2United States
143NCT00402623
(ClinicalTrials.gov)
January 200620/11/2006The Effect of Quercetin in SarcoidosisThe Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in SarcoidosisSarcoidosisDietary Supplement: quercetin;Other: placeboMaastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedN/AN/AAll18N/ANetherlands
144NCT00305552
(ClinicalTrials.gov)
February 200521/3/2006SARCOTHAL. Thalidomide in Skin SarcoidosisRandomized Controlled Trial of Thalidomide vs Placebo in Skin SarcoidosisSarcoidosisDrug: THALIDOMIDEAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/ABoth40Phase 3France
145NCT00282438
(ClinicalTrials.gov)
December 200324/1/2006Hematopoietic Stem Cell Support in Patients With Refractory SarcoidosisHematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II TrialSarcoidosisBiological: Autologous hematopoietic stem cell transplantation;Biological: Allogeneic stem cell transplantationNorthwestern UniversityNULLTerminated18 Years60 YearsAll2Phase 1/Phase 2United States
146NCT00073437
(ClinicalTrials.gov)
October 200320/11/2003A Study of Infliximab in Patients With SarcoidosisA Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade?) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement.SarcoidosisDrug: InfliximabCentocor, Inc.NULLCompleted18 YearsN/ABoth139Phase 3United States;Austria;Belgium;France;Germany;Netherlands;Sweden;Switzerland;United Kingdom;Italy
147NCT00262132
(ClinicalTrials.gov)
September 20035/12/2005Mycophenolate for Pulmonary SarcoidosisMycophenolate for Pulmonary SarcoidosisPulmonary SarcoidosisDrug: MycophenolateMedical University of South CarolinaHoffmann-La RocheTerminated18 YearsN/AAll20Phase 3United States
148NCT00001877
(ClinicalTrials.gov)
February 19993/11/1999Treatment of Pulmonary Sarcoidosis With PentoxifyllineTreatment of Pulmonary Sarcoidosis With PentoxifyllinePulmonary SarcoidosisDrug: PentoxifyllineNational Heart, Lung, and Blood Institute (NHLBI)NULLCompletedN/AN/ABoth100Phase 2United States
149NCT00000596
(ClinicalTrials.gov)
June 197827/10/1999Diffuse Fibrotic Lung DiseaseLung Diseases;Pulmonary Fibrosis;SarcoidosisDrug: prednisone;Drug: cyclophosphamide;Drug: dapsoneNational Heart, Lung, and Blood Institute (NHLBI)NULLCompleted18 YearsN/ABothPhase 2NULL